Skip to main content

INVESTORS & MEDIA

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent News
11/14/19
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 14, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that it will present at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19 at 9:10 a.m. ET . A live audio webcast of the presentation will be available under the
11/05/19
– Two late-stage microbiome clinical study readouts in ulcerative colitis and C. difficile infection anticipated in 2020 – – Debt facility secured, providing up to $50 million in additional capital; Corporate resources are expected to support operations into Q2 2021 – – Conference call at 8:30 a.m.
10/31/19
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 31, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that management will host a conference call and live audio webcast on November 5, 2019 at 8:30 a.m. ET to discuss third quarter 2019 results and provide a general business update.
There are currently no events to display.
Stock Quote
:
 
 

E-mail Alerts

Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Request Information

Obtain investor relations information by contacting us.

More

Back to top